Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00520910 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Polypodium Leucotomos Extract Decreasing UVA Premutagenic and Photoaging Markers
A Phase 2 study, sponsored by University of Miami.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT00520910 is a Phase 2 study that has completed, run by University of Miami. The registered enrollment target is 10 participants.
The verdict
NCT00520910, a Phase 2 study, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
With this study, the investigators will like to determine if taking a dose of the study medication, called Polypodium leucotomos (PL), prevents some of the changes in the skin caused by the adverse effects of UVA, a type of ultraviolet light.
Interventions
- DRUG Polypodium leucotomos
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2007-08 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00520910
The ClinicalTrials.gov registry entry for NCT00520910 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Polypodium leucotomos is the first listed.
NCT00520910 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00520910 about?
NCT00520910 is a clinical study titled "Efficacy of Polypodium Leucotomos Extract Decreasing UVA Premutagenic and Photoaging Markers". With this study, the investigators will like to determine if taking a dose of the study medication, called Polypodium leucotomos (PL), prevents some of the changes in the skin caused by the adverse effects of UVA, a type of ultraviolet light.
What is the current status of trial NCT00520910?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2007-08. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00520910?
The interventions under investigation include: Polypodium leucotomos (DRUG).
Who is sponsoring clinical trial NCT00520910?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.